Thirona Names Harm Tiddens as Chief Medical Officer

Prof. Harm Tiddens has been appointed as chief medical officer (CMO) at Thirona. The appointment reflects Thirona’s mission of bringing science to the clinics faster, to benefit all people.

“His expertise and determination in bringing image analysis methods to clinical care will bring significant value to the company,” said Eva van Rikxoort, CEO and founder of Thirona. “We have been collaborating closely with Prof. Tiddens and Erasmus Medical Center for many years. As Thirona focuses on treatment of both common and rare pulmonary diseases, rather than only on screening of the most common types, we are happy to have Prof. Tiddens bringing decades of valuable experience to the team.”
 
Tiddens is a professor of pediatric pulmonology in the department of Pediatric Respiratory Medicine and Allergology at the Erasmus Medical Center-Sophia Children’s Hospital, and an honorary professor in the department of radiology and nuclear medicine at the Erasmus Medical Center. Being the founder and director of the Erasmus MC Lung Analysis laboratory, he is an internationally respected expert in the development and validation of imaging techniques and imaging outcome measures for chronic lung diseases such as cystic fibrosis, asthma, bronchiectasis, bronchopulmonary dysplasia, and primary ciliary dyskinesia.
 
‘I am looking forward to working closely with the R&D and commercial teams, and to engage in developing innovative image analysis tools. The focal point, in my role as CMO, will be at the clinical benefits and at articulating ‘the voice of the patient,’ making sure that our technology brings a true impact to patients suffering from a wide array of lung and respiratory diseases,” said Tiddens.
 
Thirona is a global company specializing in AI-assisted medical image analysis. As a spin-off of Radboud University Medical Center in Nijmegen, Thirona is strongly rooted in scientific research and medical domain knowledge, driven by real-life challenges faced in clinical practice with focus on providing better patient care. Since its inception in 2014, Thirona has offered services and partnerships from early drug and treatment development through clinical implementation. With proven technology validated by more than 180 scientific publications, Thirona has analyzed nearly 10 million images, transforming the company from a science-based startup to a leader in advanced lung CT image analysis. 
 
Thirona focuses on translating AI-based technology into value-added solutions and services from clinical trials to clinics through partnerships and integrations. With its flagship product, LungQ, Thirona has built a track record as an expert partner for pharmaceutical and medtech companies, helping to advance treatment development in clinical trials, as well as support pulmonary clinical care worldwide.